Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

COVID-19 vaccine vaccination myocarditis heart damage inflammation RSNA imaging radiology cardiology

Moderna's updated COVID vaccine now awaits FDA authorization

"We have been working diligently for months to build ample supply, with doses ready to ship in time for the fall vaccination season in the Northern Hemisphere,” Moderna's CEO said in the announcement.

Thumbnail

Bristol Myers Squibb joins others suing US government over portions of the Inflation Reduction Act

The Drug Price Negotiation Program already has changed how the company considers the development of future oncology programs and medications. 

Thumbnail

USPSTF now recommends screening all adults for anxiety disorders

This is the first time that the task force has recommended screening for anxiety disorders in an asymptomatic adult population.

Thumbnail

Millions of Americans have 'unnecessarily' lost Medicaid coverage since April

Many did not lose coverage because they were deemed ineligible during the redetermination process, but due to procedural reasons, such as not completing required paperwork.

AI artificial intelligence stethoscope doctor

American Medical Association to advise on the use of AI in medicine

The goal is to inform users on how to best utilize AI tools while also practicing caution, as many are still in their early stages of deployment and can pose risks. 

Malissa Wood, MD. explains why Mass General created a program to combat racism and health equity.

Why health equity is important in cardiology

Malissa Wood, MD, associate chief of cardiology for diversity and equity at Massachusetts General Hospital, explains the role of health equity in cardiovascular care and what her health system is doing to address it. 

Thumbnail

How the Mark Cuban prescription drug playbook could save taxpayers billions

A new analysis reveals that insurers could put between $228 million and $2.15 billion back in taxpayers’ pockets by purchasing a series of generic oncology medications at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

Merck Januvia Janumet Steglujan Nitroso-STG-19 (NTTP) type 2 diabetes

Merck sues US government over Medicare's drug price negotiation liberties, calls program a 'sham'

Merck believes the Inflation Reduction Act-launched effort “coerces” manufacturers to enter into agreements to sell their top products at a fraction of their actual value.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.